Literature DB >> 7272931

Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: a case report and review of the literature.

A Manni, B M Arafah.   

Abstract

An 80-year-old woman with metastatic breast cancer to the lungs and bones was treated with tamoxifen, 10 mg twice daily, with arrest of disease of six month's duration. At the time of progression, increasing the dosage to 20 mg twice daily resulted in an objective remission now lasting 8+ months. This finding indicates that in this patient, the tamoxifen dosage of 40 mg/daily had a significantly higher anti-tumor effect than 20 mg/daily. Pertinent literature on the correlation of response with tamoxifen dosage is reviewed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7272931     DOI: 10.1002/1097-0142(19810815)48:4<873::aid-cncr2820480402>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

3.  The bioavailability of Tamoplex (tamoxifen). Part 3. A steady-state study in breast cancer patients.

Authors:  P H Slee; D De Vos; D Chapman; D Stevenson
Journal:  Pharm Weekbl Sci       Date:  1988-02-19

Review 4.  Tamoxifen as adjuvant therapy in breast cancer. Current status.

Authors:  P N Plowman
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 5.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

6.  Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.

Authors:  L E Stenbygaard; J Herrstedt; J F Thomsen; K R Svendsen; S A Engelholm; P Dombernowsky
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study.

Authors:  S M Watkins
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

8.  Tamoxifen metabolism: pharmacokinetic and in vitro study.

Authors:  M C Etienne; G Milano; J L Fischel; M Frenay; E François; J L Formento; J Gioanni; M Namer
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.